{"id":"metformin-pioglitazone","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"5–15","effect":"Hypoglycemia"},{"rate":"10–15","effect":"Weight gain"},{"rate":"5–10","effect":"Fluid retention / edema"},{"rate":"<0.1","effect":"Lactic acidosis (rare)"},{"rate":"1–3","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL595","moleculeType":"Small molecule","molecularWeight":"356.45"},"_dailymed":{"setId":"f6cd8da3-92cb-8800-e053-6394a90a3713","title":"PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE TABLET, FILM COATED [AVKARE]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that activates AMP-activated protein kinase (AMPK), reducing gluconeogenesis and improving insulin sensitivity in muscle and liver. Pioglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPARγ), enhancing insulin sensitivity in adipose tissue, muscle, and liver. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.","oneSentence":"This combination reduces blood glucose by increasing insulin sensitivity (pioglitazone) and decreasing hepatic glucose production while improving peripheral glucose uptake (metformin).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:13:27.863Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07289750","phase":"PHASE4","title":"The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-05-01","conditions":"T2DM, MAFLD","enrollment":80},{"nctId":"NCT03499704","phase":"PHASE4","title":"A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2020-02-11","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT07472179","phase":"NA","title":"Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS","status":"COMPLETED","sponsor":"Mst.Sumyara Khatun","startDate":"2024-08-12","conditions":"PCOS(Insulin Resistant)","enrollment":60},{"nctId":"NCT06246799","phase":"PHASE3","title":"Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-11-07","conditions":"Type 2 Diabetes (Adult Onset)","enrollment":256},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT05727761","phase":"PHASE2","title":"Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-01-01","conditions":"Oral Leukoplakia","enrollment":36},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT06571591","phase":"PHASE3","title":"Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celltrion","startDate":"2024-08-27","conditions":"T2DM","enrollment":582},{"nctId":"NCT06446531","phase":"PHASE1","title":"Prevention of Progression of Prediabetes, Obesity and CV Risk","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-09-11","conditions":"Pre-Diabetes, Weight, Body, Cardiovascular Diseases","enrollment":64},{"nctId":"NCT01471808","phase":"PHASE4","title":"Effects of Different Early Intensive Therapies on Long-term β-cell Function","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 2","enrollment":264},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT02969798","phase":"NA","title":"Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2014-01-01","conditions":"Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)","enrollment":700},{"nctId":"NCT07083401","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety Between \"BR3006\" and Co-administration of \"BR3006A\", \"BR3006B\", and \"BR3006C\" in Healthy Adult Volunteers (Fed)","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-07-05","conditions":"Diabete Mellitus","enrollment":40},{"nctId":"NCT07083388","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety Between \"BR3006\" and Co-administration of \"BR3006A\", \"BR3006B\", and \"BR3006C\" in Healthy Adult Volunteers (Fasting)","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-07-03","conditions":"Diabetes Mellitus","enrollment":52},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT05040087","phase":"NA","title":"Changing the Natural History of Type 2 Diabetes (\"CHANGE\" Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foundation for Atlanta Veterans Education and Research, Inc.","startDate":"2021-09-01","conditions":"Type 2 Diabetes","enrollment":127},{"nctId":"NCT06946628","phase":"PHASE3","title":"New Triple Therapy in Newly Diagnosed Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Diabetes Mellitus","enrollment":296},{"nctId":"NCT06107153","phase":"PHASE3","title":"Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control","status":"COMPLETED","sponsor":"University of Basrah","startDate":"2023-11-01","conditions":"Type2diabetes","enrollment":243},{"nctId":"NCT04271189","phase":"PHASE3","title":"Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2020-09-01","conditions":"Newly Diagnosed Type 2 Diabetes","enrollment":108},{"nctId":"NCT06875193","phase":"PHASE4","title":"DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2024-05-28","conditions":"Type2diabetes","enrollment":196},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT06399835","phase":"PHASE4","title":"Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2024-02-01","conditions":"Type 2 Diabetes","enrollment":120},{"nctId":"NCT05394142","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)","status":"RECRUITING","sponsor":"Fundació Sant Joan de Déu","startDate":"2022-05-24","conditions":"Polycystic Ovary Syndrome (PCOS)","enrollment":364},{"nctId":"NCT06243536","phase":"PHASE4","title":"The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"University Hospital Sestre Milosrdnice","startDate":"2024-02-01","conditions":"Type 2 Diabetes, Overweight, Disordered Eating Behaviors","enrollment":60},{"nctId":"NCT06135584","phase":"NA","title":"Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Hangzhou Normal University","startDate":"2023-11-18","conditions":"Metabolic Dysfunction-associated Fatty Liver Disease, Cirrhosis","enrollment":1000},{"nctId":"NCT05760677","phase":"PHASE1","title":"Study on the Efficacy and Safety of Chiglitazar Sodium in PCOS With T2DM","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2022-10-01","conditions":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, T2D","enrollment":142},{"nctId":"NCT05942963","phase":"PHASE4","title":"Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD","status":"UNKNOWN","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2023-10","conditions":"Non-Alcoholic Fatty Liver Disease, Type2diabetes","enrollment":240},{"nctId":"NCT04885712","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2021-05-28","conditions":"Type2 Diabetes","enrollment":378},{"nctId":"NCT04419337","phase":"PHASE2","title":"Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-09-15","conditions":"Diabetes Mellitus, Stroke","enrollment":200},{"nctId":"NCT02917629","phase":"PHASE2","title":"ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-31","conditions":"Oral Cavity Neoplasm, Oropharyngeal Neoplasm, Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7","enrollment":6},{"nctId":"NCT05629806","phase":"PHASE3","title":"Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-04-10","conditions":"Type 2 Diabetes, Blood Glucose Fluctuation","enrollment":50},{"nctId":"NCT05591235","phase":"PHASE3","title":"Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-11","conditions":"Type2diabetes, Insulin Resistance","enrollment":60},{"nctId":"NCT02303405","phase":"PHASE2","title":"Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Charles Drew University of Medicine and Science","startDate":"2014-11","conditions":"Diabetes Mellitus Type 2 With Hyperglycemia","enrollment":22},{"nctId":"NCT05422092","phase":"NA","title":"Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-09-20","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT05521633","phase":"PHASE3","title":"Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2019-06-06","conditions":"NAFLD","enrollment":96},{"nctId":"NCT05519813","phase":"PHASE4","title":"Effects of Pioglitazone Combined With Metformin on Gonadal and Metabolic Profiles in Chinese Nonobese PCOS Patients.","status":"UNKNOWN","sponsor":"Bing He","startDate":"2022-01-01","conditions":"Polycystic Ovary Syndrome","enrollment":60},{"nctId":"NCT05513729","phase":"","title":"Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-08-18","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT04976283","phase":"PHASE4","title":"Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver","status":"UNKNOWN","sponsor":"Getz Pharma","startDate":"2021-09-15","conditions":"Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD","enrollment":123},{"nctId":"NCT04867252","phase":"PHASE2","title":"Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2021-05-03","conditions":"PCOS","enrollment":88},{"nctId":"NCT03566225","phase":"EARLY_PHASE1","title":"Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-01-30","conditions":"Pioglitazone","enrollment":400},{"nctId":"NCT00571519","phase":"PHASE3","title":"Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2007-11-14","conditions":"Type 2 Diabetes Mellitus","enrollment":94},{"nctId":"NCT04013581","phase":"PHASE4","title":"Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2019-08-05","conditions":"Type 2 Diabetes Mellitus","enrollment":121},{"nctId":"NCT04662866","phase":"PHASE2","title":"Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2021-02-10","conditions":"Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders","enrollment":64},{"nctId":"NCT04027023","phase":"PHASE4","title":"Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2019-10-30","conditions":"Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT02653209","phase":"PHASE4","title":"TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2016-11-01","conditions":"Type 2 Diabetes","enrollment":525},{"nctId":"NCT02315287","phase":"PHASE4","title":"Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":190},{"nctId":"NCT03950505","phase":"PHASE4","title":"To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2020-05-29","conditions":"Non-alcoholic Steatohepatitis, Type2 Diabetes","enrollment":60},{"nctId":"NCT03452267","phase":"PHASE2, PHASE3","title":"Insulin Signaling in Skeletal Muscle","status":"WITHDRAWN","sponsor":"Wayne State University","startDate":"2019-09-01","conditions":"Insulin Sensitivity","enrollment":""},{"nctId":"NCT04392557","phase":"PHASE4","title":"Anti-inflammatory Status in DM2 Treated Patients","status":"UNKNOWN","sponsor":"University of Catanzaro","startDate":"2020-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":36},{"nctId":"NCT03796975","phase":"PHASE4","title":"Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2018-06-28","conditions":"Type 2 Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Efficacy","enrollment":120},{"nctId":"NCT03117517","phase":"EARLY_PHASE1","title":"Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2017-03-20","conditions":"Polycystic Ovarian Syndrome","enrollment":106},{"nctId":"NCT04287387","phase":"PHASE4","title":"Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-03-02","conditions":"Type2 Diabetes Mellitus","enrollment":180},{"nctId":"NCT04113889","phase":"PHASE2","title":"Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2019-10-15","conditions":"PCOS","enrollment":147},{"nctId":"NCT02694263","phase":"PHASE4","title":"Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2016-07","conditions":"Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT02292290","phase":"PHASE4","title":"Trial for People With Established Type 2 Diabetes During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2011-04","conditions":"Type 2 Diabetes","enrollment":99},{"nctId":"NCT02689843","phase":"EARLY_PHASE1","title":"Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2018-02-01","conditions":"Polycystic Ovary Syndrome","enrollment":90},{"nctId":"NCT04141163","phase":"PHASE1, PHASE2","title":"Metformin in Patients With Fragile X","status":"UNKNOWN","sponsor":"Rowan University","startDate":"2019-10-29","conditions":"Fragile X Syndrome","enrollment":40},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT00694759","phase":"NA","title":"Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2006-10","conditions":"Polycystic Ovary Syndrome","enrollment":37},{"nctId":"NCT02763007","phase":"PHASE4","title":"An Extension Study of PEAK Trial","status":"TERMINATED","sponsor":"Kun-Ho Yoon","startDate":"2016-05-18","conditions":"Diabetes Mellitus, Type 2","enrollment":41},{"nctId":"NCT02989649","phase":"","title":"Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice","status":"TERMINATED","sponsor":"Takeda","startDate":"2016-12-22","conditions":"Diabetes Mellitus, Type 2","enrollment":593},{"nctId":"NCT01882907","phase":"PHASE4","title":"Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Pusan National University Hospital","startDate":"2009-12","conditions":"Type 2 Diabetes","enrollment":287},{"nctId":"NCT00399204","phase":"PHASE4","title":"Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients","status":"WITHDRAWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2006-01","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT02231021","phase":"PHASE4","title":"The Practical Evidence of Antidiabetic Combination Therapy in Korea","status":"COMPLETED","sponsor":"Kun-Ho Yoon","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":216},{"nctId":"NCT01009580","phase":"PHASE3","title":"Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":447},{"nctId":"NCT03757923","phase":"PHASE1, PHASE2","title":"Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism","status":"UNKNOWN","sponsor":"Dow University of Health Sciences","startDate":"2018-06-18","conditions":"Menstrual Irregularities, Hyperandrogenism","enrollment":110},{"nctId":"NCT01972724","phase":"PHASE4","title":"Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-12-16","conditions":"Type II Diabetes Mellitus","enrollment":114},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01217073","phase":"PHASE2","title":"A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":685},{"nctId":"NCT02365233","phase":"PHASE4","title":"Fatty Liver Study in Patients With Type II Diabetes","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2013-05-01","conditions":"Type II Diabetes, Nonalcoholic Fatty Liver","enrollment":5},{"nctId":"NCT00232583","phase":"NA","title":"Preservation of Beta-cell Function in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2003-11","conditions":"Type 2 Diabetes Mellitus","enrollment":58},{"nctId":"NCT02733679","phase":"PHASE4","title":"Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone","status":"COMPLETED","sponsor":"NHS Tayside","startDate":"2016-09-29","conditions":"Ataxia-Telangiectasia","enrollment":27},{"nctId":"NCT00780715","phase":"PHASE4","title":"Response To Oral Agents in Diabetes (ROAD)- Pilot Study","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2008-12","conditions":"Diabetes Mellitus, Type 2","enrollment":29},{"nctId":"NCT01095666","phase":"PHASE3","title":"A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":1484},{"nctId":"NCT02823808","phase":"PHASE4","title":"Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function","status":"UNKNOWN","sponsor":"Kyunghee University Medical Center","startDate":"2017-07","conditions":"Diabetes","enrollment":96},{"nctId":"NCT02875821","phase":"PHASE4","title":"Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-04-26","conditions":"Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)","enrollment":44},{"nctId":"NCT03196362","phase":"PHASE4","title":"Impacts of PIO/MET Following Short-term Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":50},{"nctId":"NCT00532935","phase":"PHASE3","title":"MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-26","conditions":"Type 2 Diabetes Mellitus","enrollment":517},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT02298192","phase":"PHASE3","title":"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-11-21","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":420},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00722371","phase":"PHASE3","title":"MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1615},{"nctId":"NCT01028391","phase":"PHASE3","title":"30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00086515","phase":"PHASE3","title":"Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06-30","conditions":"Diabetes Mellitus, Type II","enrollment":701},{"nctId":"NCT03125694","phase":"PHASE3","title":"Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-02-01","conditions":"Uncontrolled Type 2 Diabetes Mellitus","enrollment":250},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT00972283","phase":"PHASE3","title":"Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1006},{"nctId":"NCT00481663","phase":"PHASE2","title":"A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-08-19","conditions":"Type II Diabetes Mellitus","enrollment":555},{"nctId":"NCT00362440","phase":"PHASE2","title":"Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2006-08","conditions":"HIV Lipodystrophy","enrollment":9},{"nctId":"NCT00402909","phase":"PHASE4","title":"Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-11","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT00237237","phase":"PHASE3","title":"Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-10","conditions":"Diabetes Mellitus, Type 2","enrollment":588},{"nctId":"NCT03030300","phase":"PHASE4","title":"Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Qianfoshan Hospital","startDate":"2008-01","conditions":"Type2 Diabetes","enrollment":170},{"nctId":"NCT00133718","phase":"PHASE4","title":"A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control","status":"COMPLETED","sponsor":"Asker & Baerum Hospital","startDate":"2002-01","conditions":"Type 2 Diabetes Mellitus","enrollment":120},{"nctId":"NCT00097279","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":230},{"nctId":"NCT00598793","phase":"PHASE3","title":"Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":242}],"_emaApprovals":[],"_faersSignals":[{"count":8,"reaction":"DRUG INEFFECTIVE"},{"count":4,"reaction":"ASTHENIA"},{"count":4,"reaction":"COMPLETED SUICIDE"},{"count":4,"reaction":"DIARRHOEA"},{"count":4,"reaction":"NAUSEA"},{"count":3,"reaction":"BLOOD CHOLESTEROL INCREASED"},{"count":3,"reaction":"DEPRESSION"},{"count":3,"reaction":"DIZZINESS"},{"count":3,"reaction":"DYSPNOEA"},{"count":3,"reaction":"PAIN"}],"_approvalHistory":[],"publicationCount":151,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Glucophage, Zolid"],"phase":"marketed","status":"active","brandName":"Metformin, Pioglitazone","genericName":"Metformin, Pioglitazone","companyName":"Khyber Medical University Peshawar","companyId":"khyber-medical-university-peshawar","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces blood glucose by increasing insulin sensitivity (pioglitazone) and decreasing hepatic glucose production while improving peripheral glucose uptake (metformin). Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}